Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

The U.S. Postal Service began to allow inbound mail and packages from China and Hong Kong Posts on Wednesday, less than 24 ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

FDA approves suzetrigine, a non-opioid painkiller that blocks sodium channels, offering potent relief without addiction risks.

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Dissociation is the brain’s defense against overwhelming stress, involving altered brain regions, neurotransmitters, and ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with ...